María Belén Sanchez, Bianca Vasconcelos Cordoba, Carolina Pavlovsky, Beatriz Moiraghi, Ana Varela, Rosario Custidiano, Isolda Fernandez, María Josefina Freitas, María Verónica Ventriglia, Georgina Bendek, Romina Mariano, María José Mela Osorio, Miguel Arturo Pavlovsky, Ana García de Labanca, Cecilia Foncuberta, Isabel Giere, Masiel Vera, Mariana Juni, José Mordoh, Julio Cesar Sanchez Avalos, Estrella Mariel Levy, Michele Bianchini
INTRODUCTION: Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase is considered a safe option if suitable molecular monitoring is available. However, the question arises as to which factors can contribute to the maintenance of TFR, and immunologic surveillance of the remaining leukemic cells is believed to be one of them. Argentina Stop Trial is an open-label, single-arm, multicenter trial assessing TFR after tyrosine kinase inhibitors interruption, that after more than 4 years showed a successful TFR rate of 63%...
2023: Frontiers in Immunology